Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 3% of ensitrelvir recipients, ...

An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...

Uninfected people who began taking the antiviral within 72 hours of symptoms first appearing in a household member were ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two ...

The COVID-19 pandemic took hold across the globe 5 years ago this month. The Conversation talked to Former Former East-West ...

The results mean that the drug lowered the risk of getting COVID-19 by 67%. The idea of using an antiviral treatment to protect people at high risk of infection isn’t new. The popular flu ...